tiprankstipranks
Trending News
More News >
Pa Shun International Holdings Limited (HK:0574)
:0574
Hong Kong Market

Pa Shun International Holdings Limited (0574) AI Stock Analysis

Compare
0 Followers

Top Page

HK:0574

Pa Shun International Holdings Limited

(0574)

Select Model
Select Model
Select Model
Neutral 41 (OpenAI - 4o)
Rating:41Neutral
Price Target:
HK$0.05
▼(-4.00% Downside)
The overall stock score is primarily impacted by the company's poor financial performance, with significant challenges in revenue, profitability, and cash flow. Technical analysis suggests a neutral trend, but the lack of positive momentum and valuation concerns due to negative earnings and no dividend yield further weigh down the score.
Positive Factors
Diversified Revenue Streams
The company's diversified revenue streams through direct sales, bulk orders, and partnerships provide resilience against market fluctuations and enhance long-term stability.
Strategic Partnerships
Strategic partnerships help optimize operational efficiency and cost management, contributing to sustained profitability and competitive advantage.
Global Market Reach
The company's ability to deliver products globally indicates strong supply chain management and potential for market expansion, supporting long-term growth.
Negative Factors
Declining Revenue
Ongoing revenue decline suggests weakening market position and challenges in maintaining competitive edge, impacting long-term financial health.
Negative Equity
Negative equity highlights financial instability and potential insolvency risks, limiting the company's ability to invest in growth opportunities.
Poor Cash Flow
Negative free cash flow indicates cash outflows exceed inflows, challenging the company's ability to sustain operations and invest in future growth.

Pa Shun International Holdings Limited (0574) vs. iShares MSCI Hong Kong ETF (EWH)

Pa Shun International Holdings Limited Business Overview & Revenue Model

Company DescriptionPa Shun International Holdings Limited, an investment holding company, engages in the pharmaceutical distribution activities in the People's Republic of China. It operates through three segments: Pharmaceutical Distribution, Self-Operated Retail Pharmacies, and Pharmaceutical Manufacturing. The Pharmaceutical Distribution segment sells pharmaceutical products to wholesalers, franchise retail pharmacy chain stores, and hospitals and other medical institutions in rural areas. The Self-Operated Retail Pharmacies segment engages in the sale of pharmaceutical and healthcare products, cosmetic products, and daily necessities in self-operated retail pharmacies. The Pharmaceutical Manufacturing segment sells pharmaceutical products manufactured by the company. The company was formerly known as Pa Shun Pharmaceutical International Holdings Limited and changed its name to Pa Shun International Holdings Limited in June 2017. The company was incorporated in 2011 and is based in San Po Kong, Hong Kong. Pa Shun International Holdings Limited is a subsidiary of Praise Treasure Limited.
How the Company Makes MoneyPa Shun International Holdings Limited generates revenue through multiple streams, primarily from the sale of its manufactured consumer goods, including electronics and home appliances. The company operates on a business model that involves designing, producing, and distributing these products to various retailers and wholesalers both domestically and internationally. Key revenue streams include direct sales to retailers, bulk orders from distributors, and partnerships with international brands for private label manufacturing. Additionally, the company may benefit from value-added services such as after-sales support and warranty services, enhancing customer loyalty and driving repeat business. Strategic partnerships with suppliers and logistics companies also play a crucial role in optimizing operational efficiency and cost management, further contributing to its profitability.

Pa Shun International Holdings Limited Financial Statement Overview

Summary
Pa Shun International Holdings Limited is facing significant financial challenges across all verticals. The income statement reveals declining revenues and persistent losses, while the balance sheet shows negative equity and high leverage. Cash flow analysis indicates poor cash generation and sustainability issues. The company needs strategic restructuring to improve its financial health.
Income Statement
25
Negative
The company has experienced significant revenue decline over the years, with a notable drop from 2019 to 2024. Gross profit margins have been volatile, and the net profit margin has been negative in recent years, indicating ongoing losses. The EBIT and EBITDA margins are also negative, reflecting operational inefficiencies and financial challenges.
Balance Sheet
20
Very Negative
The balance sheet shows a concerning financial position with negative stockholders' equity, indicating potential insolvency risks. The debt-to-equity ratio cannot be calculated due to negative equity, but high total liabilities relative to assets suggest significant leverage. The equity ratio is negative, further highlighting financial instability.
Cash Flow
30
Negative
The company has consistently reported negative free cash flow, indicating cash outflows exceed inflows from operations. The operating cash flow to net income ratio is negative, reflecting poor cash generation relative to net losses. The free cash flow to net income ratio is also negative, underscoring cash flow challenges.
BreakdownTTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue86.42M86.55M129.43M71.78M85.91M474.83M
Gross Profit13.74M17.06M29.43M13.30M11.06M17.70M
EBITDA99.00K2.89M19.65M-3.26M-11.85M-11.10M
Net Income-59.80M-15.31M2.35M-43.38M-330.40M-419.19M
Balance Sheet
Total Assets161.96M179.65M206.57M136.09M468.59M503.19M
Cash, Cash Equivalents and Short-Term Investments3.56M15.97M16.51M1.90M2.27M5.26M
Total Debt40.42M44.03M165.97M108.71M99.01M102.71M
Total Liabilities310.43M315.68M322.67M251.60M251.59M225.20M
Stockholders Equity-148.47M-136.04M-116.10M-115.52M-58.50M277.98M
Cash Flow
Free Cash Flow5.39M-1.77M-35.00M-2.35M-22.12M-6.59M
Operating Cash Flow5.49M-1.68M-34.93M-2.32M-21.89M-6.51M
Investing Cash Flow-596.00K-88.00K-65.00K2.98M24.97M-2.43M
Financing Cash Flow-5.96M1.23M49.61M-1.02M-6.07M3.17M

Pa Shun International Holdings Limited Technical Analysis

Technical Analysis Sentiment
Positive
Last Price0.05
Price Trends
50DMA
0.05
Negative
100DMA
0.05
Negative
200DMA
0.04
Positive
Market Momentum
MACD
>-0.01
Negative
RSI
52.38
Neutral
STOCH
71.14
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:0574, the sentiment is Positive. The current price of 0.05 is above the 20-day moving average (MA) of 0.05, below the 50-day MA of 0.05, and above the 200-day MA of 0.04, indicating a neutral trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 52.38 is Neutral, neither overbought nor oversold. The STOCH value of 71.14 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:0574.

Pa Shun International Holdings Limited Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
52
Neutral
HK$86.83M-13.14-11.91%-4.50%75.98%
51
Neutral
$7.86B-0.30-43.30%2.27%22.53%-2.21%
48
Neutral
HK$59.51M-19.93%-2.91%55.41%
47
Neutral
HK$48.29M-2.40%-40.37%-112.64%
41
Neutral
HK$69.32M-1.07-9.71%-279.92%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
HK:0574
Pa Shun International Holdings Limited
0.05
0.01
25.00%
HK:1889
Sanai Health Industry Group Company Limited
0.51
0.10
22.89%
HK:0911
Qianhai Health Holdings Ltd.
0.30
0.03
11.11%
HK:0401
Wanjia Group Holdings Ltd.
0.12
0.06
100.00%
HK:6108
New Ray Medicine International Holding Ltd.
0.26
-0.17
-39.53%
HK:8307
Medicskin Holdings Ltd.
0.15
-0.04
-21.05%

Pa Shun International Holdings Limited Corporate Events

Pa Shun International Announces Interim Results for H1 2025
Aug 11, 2025

Pa Shun International Holdings Limited, incorporated in the Cayman Islands, has announced its unaudited condensed consolidated interim results for the six months ending June 30, 2025. The announcement complies with the listing rules of the Hong Kong Stock Exchange. This release provides stakeholders with insights into the company’s financial performance and strategic positioning in the market.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Dec 13, 2025